BioLineRx (BLRX) Competitors $0.55 +0.01 (+1.87%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends BLRX vs. GALT, DMAC, TIL, MDWD, ADAP, LFVN, ACTU, TSVT, FULC, and GOSSShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Galectin Therapeutics (GALT), DiaMedica Therapeutics (DMAC), Instil Bio (TIL), MediWound (MDWD), Adaptimmune Therapeutics (ADAP), LifeVantage (LFVN), Actuate Therapeutics (ACTU), 2seventy bio (TSVT), Fulcrum Therapeutics (FULC), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. Galectin Therapeutics DiaMedica Therapeutics Instil Bio MediWound Adaptimmune Therapeutics LifeVantage Actuate Therapeutics 2seventy bio Fulcrum Therapeutics Gossamer Bio Galectin Therapeutics (NASDAQ:GALT) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends. Which has more risk & volatility, GALT or BLRX? Galectin Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Does the MarketBeat Community prefer GALT or BLRX? BioLineRx received 158 more outperform votes than Galectin Therapeutics when rated by MarketBeat users. Likewise, 72.77% of users gave BioLineRx an outperform vote while only 59.32% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformGalectin TherapeuticsOutperform Votes34759.32% Underperform Votes23840.68% BioLineRxOutperform Votes50572.77% Underperform Votes18927.23% Do insiders and institutionals hold more shares of GALT or BLRX? 11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 52.7% of Galectin Therapeutics shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, GALT or BLRX? Galectin Therapeutics has higher earnings, but lower revenue than BioLineRx. Galectin Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$41.07M-$0.73-3.86BioLineRx$17.05M2.56-$60.61M-$0.45-1.21 Is GALT or BLRX more profitable? Galectin Therapeutics' return on equity of 0.00% beat BioLineRx's return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -163.15% BioLineRx N/A -225.62%-51.71% Do analysts rate GALT or BLRX? Galectin Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 290.76%. BioLineRx has a consensus price target of $21.00, suggesting a potential upside of 3,751.80%. Given BioLineRx's higher probable upside, analysts plainly believe BioLineRx is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer GALT or BLRX? In the previous week, Galectin Therapeutics had 11 more articles in the media than BioLineRx. MarketBeat recorded 14 mentions for Galectin Therapeutics and 3 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.17 beat Galectin Therapeutics' score of 0.04 indicating that BioLineRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBioLineRx beats Galectin Therapeutics on 9 of the 14 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.58M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-1.214.8389.0213.30Price / Sales2.56372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book3.037.876.085.74Net Income-$60.61M$153.61M$119.07M$225.93M7 Day Performance19.04%-2.00%-1.84%-1.32%1 Month Performance15.75%-7.47%-3.65%0.60%1 Year Performance-64.13%31.80%31.62%26.23% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx1.9598 of 5 stars$0.55+1.9%$21.00+3,751.8%-67.9%$43.58M$17.05M-1.2140News CoverageGALTGalectin Therapeutics1.6982 of 5 stars$2.82+2.2%$11.00+290.8%+50.8%$172.91MN/A0.009Analyst UpgradeAnalyst RevisionNews CoverageDMACDiaMedica Therapeutics1.8921 of 5 stars$4.02-0.5%$7.00+74.1%+62.8%$172.75MN/A0.0020TILInstil Bio2.8201 of 5 stars$23.36-10.8%$145.00+520.7%+208.2%$170.98MN/A0.0049MDWDMediWound1.8385 of 5 stars$16.78+6.2%$29.00+72.8%+96.0%$170.43M$18.69M0.0080Upcoming EarningsADAPAdaptimmune Therapeutics2.1006 of 5 stars$0.66-1.5%$3.16+375.8%+54.9%$170.08M$60.28M-3.02449Analyst RevisionHigh Trading VolumeLFVNLifeVantage2.7198 of 5 stars$12.93-4.6%N/A+121.0%$169.84M$200.16M40.41260ACTUActuate TherapeuticsN/A$8.67-2.6%N/AN/A$169.34MN/A0.0010TSVT2seventy bio2.4533 of 5 stars$3.11-3.4%$9.00+189.4%+78.7%$166.12M$100.39M0.00440FULCFulcrum Therapeutics3.5558 of 5 stars$2.99-0.7%$9.33+212.2%-35.7%$162.35M$2.81M0.00100Analyst RevisionNews CoverageGOSSGossamer Bio4.4297 of 5 stars$0.70-2.8%$9.20+1,220.9%-16.9%$161.98MN/A0.00180 Related Companies and Tools Related Companies GALT Competitors DMAC Competitors TIL Competitors MDWD Competitors ADAP Competitors LFVN Competitors ACTU Competitors TSVT Competitors FULC Competitors GOSS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLRX Stock Alerts